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Introduction
Patients with systemic inﬂ  ammatory conditions such as 
systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (RA) have been shown to develop premature and 
accelerated atherosclerosis [1,2], but it remains unclear 
whether this occurs in systemic sclerosis (SSc). Involve-
ment of the microvasculature is one of the earliest 
features of SSc, preceding and potentially contributing 
via tissue ischemia to the widespread ﬁ   brosis  charac ter istic 
of this condition. Pathological changes include dis  rup  tion 
of the endothelium, mononuclear cell inﬁ  ltration of the 
vessel wall, frank obliterative lesions, and progres  sive loss 
of capillaries. Th   ere is also disruption of neuro  endothelial 
control mechanisms of vascular tone. Th  ese  microvascular 
abnormalities contribute to the patho  genesis of pulmonary 
arterial hypertension (PAH), scleroderma renal crisis, 
Raynaud’s phenomenon, and digital ulceration.
Although macrovascular disease was not originally 
considered a feature of SSc, multiple studies have 
revealed an increased prevalence of large-vessel disease 
of the upper and lower limbs in patients with SSc [3,4]. 
Th  e prevalence of coronary artery and cerebrovascular 
disease in SSc, however, remains unclear. Th   e purposes of 
this review are to summarize the evidence for macro-
vascular disease, cardiovascular risk factors, and surro-
gate measures of cardiovascular disease in SSc and to 
explore potential pathogenic mechanisms of accelerated 
atherosclerosis in patients with SSc.
Clinical cardiovascular disease
Peripheral vascular disease
Peripheral vascular disease in patients with SSc has been 
reported in uncontrolled observational studies that used 
techniques such as the ankle brachial pressure index 
(ABPI), lower-limb Doppler ultrasound, and angiography 
[5-7]. Two studies have compared the prevalence of 
peripheral vascular disease in patients with SSc with that 
in controls. Veale and colleagues [3] measured the 
prevalence of intermittent claudication in a cohort of 46 
patients with SSc by using a validated World Health 
Organi  zation questionnaire and compared the ﬁ  ndings 
with those of the Edinburgh Artery Study, a cross-
sectional popula  tion-based study of a neighboring region. 
Th   e rates of prevalence of intermittent claudication were 
21.7% in the SSc cohort and 4.5% in the Edinburgh Artery 
Study. Although the two groups were not directly 
comparable, the authors suggested that the size of the 
diﬀ  erence and the fact that the SSc cohort was younger 
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© 2011 BioMed Central Ltdand predomi  nantly female strengthened the signiﬁ  cance 
of their ﬁ  ndings. Th   e authors went on to perform a case 
control study of 54 patients with SSc and 43 age- and sex-
matched controls [4]. Peripheral vascular disease, as 
diagnosed by the ABPI, was present in 17% of patients 
with SSc and in none of the controls (P = 0.003) [4]. Th  ere 
was no diﬀ  erence in the traditional cardiovascular risk 
factor proﬁ  le between the two groups.
Th  e contribution of traditional cardiovascular risk 
factors to peripheral vascular disease was examined in a 
retrospective review of 26 angiograms performed in a 
single SSc cohort [5]. Th  e authors demonstrated a 
signiﬁ   cant association between the presence of tradi-
tional cardiovascular risk factors and proximal, but not 
distal, vascular disease in the lower limb. Th  ough  limited 
by a small sample size, this study suggests that, in at least 
some cases, peripheral vascular disease in SSc is not 
atherosclerotic but related to the vasculopathy of SSc 
itself. In keeping with this possibility, Youssef and 
colleagues [8]  reported chronic obliterative thrombo-
angiitis on histological examination of an amputated limb 
in a woman with limited SSc. Involvement of the vasa 
vasorum has been suggested as a potential cause of 
macrovascular disease in SSc [9].
Cerebrovascular disease
Few studies have investigated the prevalence of cerebro-
vascular disease in SSc. Youssef and colleagues [8] 
performed a retrospective cohort study comparing the 
prevalence of macrovascular disease in 31 patients with 
limited SSc and 31 matched controls. Cerebrovascular 
disease was deﬁ   ned as a transient ischemic attack or 
completed stroke diagnosed by a physician, the presence 
of carotid or vertebral artery bruits, Doppler evidence of 
carotid or vertebral artery disease, or angiographic 
evidence of carotid artery stenosis. Th  e investigators 
found no signiﬁ  cant diﬀ  erence in cerebrovascular disease 
between patients with SSc and controls (26% versus 19%, 
respectively; P = 0.544). In contrast, Ho and colleagues 
[4] examined the prevalence of carotid artery disease by 
using B mode and color Doppler ultrasound and demon-
strated carotid artery stenosis in 64% of patients with SSc 
and 35% of age- and sex-matched controls (P = 0.007).
Cardiac disease
Coronary artery disease
    Early autopsy studies of patients with SSc suggested that 
atherosclerotic disease of the coronary arteries was 
infrequent. Several case series demonstrated myocardial 
infarction (MI) in the presence of patent coronary 
arteries, suggesting primary myocardial disease or 
vasospasm [10,11]. Th   e most quoted of these studies was 
a retrospective review of 52 autopsies of patients with 
SSc; in that review, 26 (50%) patients were found to have 
foci of myocardial necrosis [11]. Of these 26 patients, 23 
had widely patent extramural coronary arteries. A 
common pattern in those with myocardial involvement 
was contraction band necrosis, which is a histo  patho-
logical correlate of reperfusion injury. Th  e authors 
therefore hypothesized that the observed myocardial 
damage was due to intermittent hypoperfusion of the 
myocardium secondary to Raynaud’s phenomenon of the 
intramural coronary arteries. It is important to note that 
these autopsy studies were performed in an era when SSc 
was largely untreated and patients were more likely to 
succumb to SSc-related complications such as sclero-
derma renal crisis. Th  is temporal change is reﬂ  ected in 
an analysis of mortality over a 30-year period from 1972 
to 2002, in which 10-year survival improved from 54% to 
66% and non-SSc-related deaths increased from 20% to 
50% of all deaths [12].
Th  ere are no large cohort studies examining the 
prevalence of coronary artery disease in living patients 
with SSc. Most studies to date have reported the presence 
of coronary atherosclerosis in SSc patients who undergo 
coronary angiography for clinical indications. For 
example, Akram and colleagues [13] reviewed all 172 
coronary angiograms performed in a single SSc referral 
center from 1998 to 2004 and found coronary artery 
disease in 22%. Th  ese authors calculated standardized 
prevalence ratios based on age, gender, and presenting 
cardiac symptom and, using published probability tables 
relating pretest likelihood of coronary artery disease to 
angiographic abnormalities, concluded that the preva-
lence of coronary artery disease was no greater than that 
expected in individuals without SSc. Th   is was, however, a 
retrospective study with no control group. Furthermore, 
patients included in the study had diﬀ  ering indications 
for angiography and the number of patients undergoing 
angiogram for suspected coronary artery disease was not 
reported. When grouped according to predominant 
cardiac symptom, only 27 patients had typical angina, 29 
had atypical angina, and 116 had dyspnea on exertion.   
Th  ere was also a very high prevalence of PAH (63% of 
patients with limited disease and 85% of patients with 
diﬀ   use disease), perhaps accounting for a signiﬁ  cant 
proportion of reported symptoms. Th  is was therefore a 
study of a highly selected group rather than consecutive 
patients with SSc.
Th   e relationship between clinical events and coronary 
angiogram ﬁ   ndings was examined in a retrospective 
review of all SSc patients admitted to a single institution 
with acute MI over a 20-year period [14]. MI was deﬁ  ned 
as electrocardiographic changes and an at least twofold 
increase in serum myocardial creatinine kinase (CK) 
level. Th   e authors identiﬁ  ed 11 patients, 3 of whom had 
normal coronary arteries on cardiac catheterization. Th  e 
odds ratio of ﬁ  nding normal coronary arteries in acute 
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patients with SSc compared with the general population. 
Of the 11 cases, however, 7 had signiﬁ  cant renal impair-
ment and 4 had frank scleroderma renal crisis. Th  is  may 
aﬀ  ect the validity of these results given that the clearance 
of CK is reduced in renal failure and an elevated CK 
formed part of the deﬁ  nition of MI.
Another angiographic study assessed the overlap 
between PAH and coronary artery disease [15]. One 
hundred twenty consecutive patients with SSc were 
assessed clinically for cardiorespiratory disease. Both 
right heart catheterization and coronary angiography 
were performed for suspected PAH in 20 patients and for 
suspected coronary artery disease in 10 patients. Th  ere 
was considerable overlap of diagnoses; PAH was found in 
12 of the 20 suspected PAH cases and in 2 of the 10 
suspected coronary artery disease cases. Similarly, 
coronary artery stenosis was found in 9 of the 20 
suspected PAH cases and in 6 of the 10 suspected 
coronary artery disease cases. All eight of the patients 
who underwent revascularization for coronary artery 
disease improved signiﬁ  cantly in 6-minute walk distance 
and the Borg dyspnea index. Th   e authors concluded that 
coronary artery disease symptoms may be atypical in 
patients with SSc and that revascularization may improve 
symptoms and physical activity in selected patients.
Few angiographic studies have been performed in 
asymptomatic patients with SSc. Tarek and colleagues [16] 
performed coronary catheterization in 9 patients with 
diﬀ  use SSc and 5 patients with limited SSc, all of whom 
were female and asymptomatic. Th  e authors detected a 
total of 19 angiographic abnormalities, with signiﬁ  cant 
coronary artery stenosis in 3 patients with limited disease. 
Other angiographic ﬁ   ndings included coronary artery 
ectasia, slow ﬂ  ow, tortuosity, calciﬁ  ca  tion, and spasm. Th  e 
prevalence of traditional cardio  vascular risk factors in this 
cohort was low, with hyper  tension in 3 patients but no 
other risk factors of note. While the study was small and 
uncontrolled, the ﬁ   ndings suggest that angiographic 
abnormalities may be higher than previously thought in 
asymptomatic patients with SSc.
Primary myocardial disease
Microvascular disease of the myocardium can also result 
in angina pectoris or acute MI (or both) in SSc. It has 
been proposed that recurrent vasospasm, together with 
irreversible structural lesions, leads to repeated focal 
ischemia and eventual myocardial ﬁ   brosis [17]. When 
advanced, this manifests as systolic and diastolic dysfunc-
tion, leading in some cases to overt congestive cardiac 
failure. Myocardial perfusion in SSc has been found to be 
impaired by using cardiac catheterization [18], radio-
nuclide imaging [19], and echocardiographic techniques 
[20]. One study of 26 unselected patients with diﬀ  use SSc 
found evidence of cardiac abnormalities on thallium-
perfusion scanning in 20 patients, only 6 of whom had 
symptomatic cardiac disease [19]. Of the 7 patients who 
had exercise-induced defects and who underwent 
subsequent coronary angiography, all had normal coro-
nary arteries. Furthermore, patients with exercise-
induced defects that were more signiﬁ  cant had lower left 
and right ventricular ejection fractions on radionuclide 
ventriculography. Th  is led the authors to conclude that 
abnormalities of myocardial perfusion in SSc are due to a 
disturbance of the myocardial microcirculation and that 
this, in turn, contributes to ventricular dysfunction.
In recent years, modalities that are more sensitive have 
been developed to detect primary myocardial involve-
ment in SSc. Non-standard echocardiographic tech  niques 
such as pulsed tissue Doppler and strain rate imaging 
better quantify regional myocardial function than 
standard echocardiography. Cardiac magnetic resonance 
imaging (MRI) has been used to image myocardial 
ﬁ  brosis in SSc [21]; however, histological conﬁ  rmation of 
areas of MRI signal abnormality is lacking. N-terminal 
pro-brain natriuretic peptide (NT-proBNP) is an amino 
acid produced from cleavage of the prohormone proBNP, 
which is released from the heart in response to pressure 
or volume overload or both. In the general population, it 
has diagnostic and prognostic value in heart failure and 
other cardiovascular diseases [22]. In SSc, NT-proBNP 
has been investigated as a biomarker of primary myo-
cardial disease and is elevated in patients with primary 
myocardial dysfunction as determined by tissue Doppler 
echocardiography [23]. It has the advantage of being 
easily performed and widely applied; however, it is not 
speciﬁ   c for primary myocardial disease, as it is also 
elevated in PAH.
Surrogate markers of atherosclerosis
Various surrogate markers of atherosclerosis have been 
investigated in SSc but with conﬂ  icting results.
Carotid intima-media thickness
Carotid intima-media thickness (CIMT) as measured by 
high-resolution ultrasound is a well-validated marker of 
subclinical atherosclerosis. Increased CIMT has been 
shown to correlate with traditional cardiovascular risk 
factors and to predict future vascular events in healthy 
individuals [24]. A meta-analysis of CIMT in rheumatic 
diseases, including RA, SLE, and SSc, found that CIMT 
was signiﬁ  cantly increased in this population compared 
with healthy, age- and sex-matched controls [25]. Th  e 
pooled result of the SSc studies demonstrated a greater 
CIMT in patients with SSc than controls, suggesting an 
increased prevalence of subclinical atherosclerosis. Th  e 
eﬀ  ect size seen in SSc was also greater than those in RA 
and SLE. Despite this ﬁ  nding, a number of individual 
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SSc (Table 1) [26-31].
Correlates of increased CIMT have also been assessed in 
several studies. Bartoli and colleagues [32] demon strated 
increased CIMT in patients with SSc and found an asso-
ciation between higher CIMT and the deletion (D) poly-
morphism of the angiotensin-converting enzyme (ACE) 
gene. Th   e ACE DD genotype has been shown to be asso-
cia  ted with atherosclerosis in the general population [33]. 
Another group has demonstrated an association between 
increased CIMT in patients with SSc and the presence of 
antibodies to heat-shock protein-65 [34], which are also 
implicated in the pathogenesis of athero  sclerosis.
Flow-mediated dilatation
Flow-mediated dilatation (FMD) is a marker of 
endothelium-dependent vasodilatation and is measured 
using high-resolution ultrasound at the brachial artery. In 
healthy arteries exposed to a short period of occlusion by 
tourniquet, restoration of blood ﬂ  ow results in transient 
vasodilatation. Impaired FMD is associated with the 
presence of traditional cardiovascular risk factors [35] 
and is independently predictive of incident cardiovascular 
events [36]. FMD is usually performed in concert with 
nitrate-mediated dilatation, which is assessed after 
sublingual nitroglycerin administration and reﬂ  ects 
endothelium-independent vasodilatation. Many, but not 
all, studies have found FMD to be decreased in SSc 
compared with controls (Table 2) [27,28,37-44]. Some 
groups have found nitrate-mediated dilatation to be 
reduced also [40,41,45], and this could suggest a co-
existing functional or structural abnormality of arterial 
smooth muscle, adventitia, or both. Interestingly, in the 
studies in which no diﬀ  erence in FMD was detected, the 
majority of patients had limited rather than diﬀ  use 
disease [27,44], suggesting more endothelial dysfunction 
in diﬀ  use SSc.
Arterial stiff  ness
Arterial stiﬀ  ness is measured by the techniques of pulse 
wave analysis (PWA) and pulse wave velocity (PWV), and 
carotid-femoral PWV is considered the current ‘gold-
standard’ measurement of arterial stiﬀ  ness [46]. PWA, 
expressed as the augmentation index (AI), reﬂ  ects the 
stiﬀ   ness of the aorta, whereas carotid-femoral PWV 
reﬂ  ects the velocity of the pulse wave along the aortic and 
aorto-iliac pathways. Increased arterial stiﬀ  ness results in 
premature return of reﬂ   ected waves in late systole, 
causing increased load on the left ventricle and increased 
myocardial oxygen demand. Arterial stiﬀ  ness is increased 
in the presence of cardiovascular risk factors [47] and is 
an independent predictor of cardiovascular events and 
cardiovascular and all-cause mortality across a wide 
range of patient populations [48].
Arterial stiﬀ  ness has been examined in SSc but with 
varying results (Table 3) [27,31,37,39,44,49,50]. Cypiene 
and colleagues [37] found arterial stiﬀ  ness as measured 
by PWA and PWV to be elevated in 17 patients with 
diﬀ  use SSc compared with 34 healthy controls. Timar 
and colleagues [49] found that AI and PWV were both 
elevated in 40 patients with SSc and in 35 controls. Th  e 
investigators also found that PWV was higher in patients 
with limited disease than in those with diﬀ  use disease 
and that PWV was positively correlated with disease 
duration. Th  e authors therefore postulated that PWV 
may be a better measure of arterial stiﬀ  ness than AI in 
SSc. Another group found arterial stiﬀ  ness to be elevated 
in patients with SSc or mixed connective tissue disease 
Table 1. Studies of carotid intima-media thickness in systemic sclerosis
  Total SSc,   lSSc,   dSSc,   Controls,  
Reference number  number  number  number  Outcomea Other  fi  ndings
Lekakis et al. [40], 1998  12  0  12  12   
Cheng et al. [30], 2003  52  33  19  21   
Zakopoulos et al. [29], 2003  40  15  30  45   
Bartoli et al. [32], 2007  53  45  8  53    CIMT is higher in patients carrying D allele of ACE 
          gene.
Bartoli et al. [38], 2007  35  11  24  20    No correlation between CIMT and cardiovascular 
            risk factors was found.
Sherer et al. [34], 2007  44  38  6  32    CIMT is higher in patients with IgM anti-HSP-65.
Szucs et al. [28], 2007  29  19  10  29    CIMT correlates with age and disease duration.
Roustit et al. [27], 2008  42  33  9  33   
Hettema et al. [26], 2008  49  45  4  32   
Liu et al. [31], 2011  25  17  8  25   
aCarotid intima-media thickness (CIMT) in patients with systemic sclerosis (SSc) relative to controls: , CIMT higher in patients with SSc than controls; , no diff  erence 
in CIMT between patients and controls. ACE, angiotensin-converting enzyme; anti-HSP-65, anti-heat shock protein-65; D, deletion; dSSc, diff  use systemic sclerosis; 
lSSc, limited systemic sclerosis.
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of soluble markers of endothelial activation, including 
plasma nitrate, soluble E-selectin, and soluble vascular 
cell adhesion molecule-1 (VCAM-1) [44]. Liu and 
colleagues [31] found regional diﬀ   erences in arterial 
stiﬀ  ness with increased PWV in the forearm and arm but 
not the upper arm, aorta, or leg in patients with SSc 
compared with controls. Th   is suggests preferential 
involve  ment of the muscular arteries of the forearm [31]. 
Several other studies have been unable to demonstrate a 
signiﬁ  cant diﬀ  erence in arterial stiﬀ  ness between patients 
with SSc and controls [27,50].
Coronary calcium score
A novel method of assessing coronary artery disease is 
the coronary calcium score, as determined by multi-
detector computed tomography. Th   is technique measures 
coronary artery calciﬁ   cation that occurs in athero-
sclerotic plaque. In a cross-sectional study of 17 patients 
with SSc free from clinical cardiovascular disease and 17 
controls, coronary calciﬁ  cation was present in 9 patients 
with SSc and 3 controls (P = 0.03) [51]. Th  e  correlation 
between coronary calciﬁ  cation and angiographic ﬁ  ndings 
in the SSc population is unknown and larger studies are 
required to investigate this association.
Table 2. Studies of fl  ow-mediated dilatation in systemic sclerosis
  Total SSc,   lSSc,   dSSc,   Controls,  
Reference number  number  number  number  Outcomea Other  fi  ndings
Lekakis et al. [40], 1998  12  0  12  12   NMD  . Improvement was found in FMD after 
          estrogen  administration.
Andersen et al. [44], 2002  24  20  4  24   NMD  
D’Andrea et al. [42], 2007  33  18  15  33   NMD  . FMD was a predictor of middle LV strain 
          on  TTE.
Szucs et al. [28], 2007  29  19  10  29   NMD  
Sfi  kakis et al. [39], 2007  24  6  18  52   NMD  . Four weeks of bosentan led to 
          improvement  in  FMD.
Bartoli et al. [38], 2007  35  24  11  20    No correlation between FMD and cardiovascular 
            risk factors was found.
Roustit et al. [27], 2008  42  33  9  33   NMD  
Cypiene et al. [37], 2008  17  0  17  34   NMD  
Rollando et al. [43], 2010  43  30  13  27    FMD was inversely correlated with microvascular 
            damage on nailfold videocapillaroscopy.
Rossi et al. [45], 2010  14  10  4  14   NMD  
aFlow-mediated dilatation (FMD) in patients with systemic sclerosis (SSc) relative to controls: , lower in patients with SSc than controls; , no diff  erence 
between patients with SSc and controls. dSSc, diff  use systemic sclerosis; lSSc, limited systemic sclerosis; LV, left ventricle; NMD, nitroglycerin-mediated dilatation; 
TTE, trans-thoracic echocardiography.
Table 3. Studies of arterial stiff  ness in systemic sclerosis
  Total SSc,   lSSc,   dSSc,   Controls,  
Reference number  number  number  number  Outcomea Other  fi  ndings
Andersen et al. [44], 2002  24  20  4  24  AI  
Sfi  kakis et al. [39], 2007  24  6  18  52  AI   Four weeks of bosentan therapy had no eff  ect on 
          AI.
Roustit et al. [27], 2008  42  33  9  33  PWV  
Cypiene et al. [37], 2008  17  0  17  34  AI 
        P W V    
Timar et al. [49], 2008  40  31  9  35  AI  PWV was higher in patients with limited disease
        P W V     and correlated with disease duration.
Peled et al. [50], 2009  18  -  -  13  AI  No  diff  erence was found between patients with 
            SSc with and without PAH.
Liu et al. [31], 2011  25  17  8  25  PWV  at   PWV  at upper arm, aorta, and leg
        forearm  and  arm
aArterial stiff  ness in patients with systemic sclerosis (SSc) relative to controls: , higher in patients with SSc than controls; , no diff  erence between patients with SSc 
and controls. AI, augmentation index; dSSc, diff  use systemic sclerosis; lSSc, limited systemic sclerosis; PAH, pulmonary arterial hypertension; PWV, pulse wave velocity.
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Th   ere is limited information regarding the prevalence of 
traditional cardiovascular risk factors in SSc. A study of 
40 patients with SSc and 45 controls demonstrated no 
diﬀ   erence in blood pressure on 24-hour ambulatory 
blood pressure monitoring [29]. Signiﬁ  cantly lower levels 
of high-density lipoprotein were recorded in one study of 
24 female patients with limited SSc compared with 24 
healthy controls [52], whereas another study found signi-
ﬁ    cantly elevated lipoprotein [a] in 31 female patients with 
SSc compared with 33 healthy controls but no signiﬁ  cant 
diﬀ  erence in other cholesterol parameters or triglycerides 
[53]. Other novel cardiovascular risk factors that have 
been reported as elevated in SSc include oxidized low-
density lipoprotein and endothelin [54].
Potential mechanisms of cardiovascular disease in 
systemic sclerosis
Infl  ammation
Inﬂ  ammation is a key component of atherosclerosis [55], 
and it is well established that even a relatively minor 
elevation of inﬂ  ammatory markers (such as C-reactive 
protein) is predictive of cardiovascular events in the 
general population [56]. Cardiovascular disease occurs 
more frequently in patients with chronic inﬂ  ammatory 
diseases such as SLE [1] and RA [2] than in the general 
population, and although the precise mechanism of 
accelerated atherosclerosis in these conditions has not 
been fully elucidated, various cellular and cytokine 
pathways have been implicated. Excess cytokine produc-
tion and release are also key events in the pathogenesis of 
SSc. Numerous inﬂ  ammatory mediators that have been 
implicated in the pathogenesis of atherosclerosis, includ-
ing tumor necrosis factor-alpha, interleukin-6, and high-
sensitivity C-reactive protein, have been demonstrated to 
be increased in patients with SSc compared with controls 
[57]. Th  e relationship between these mediators and 
cardio  vascular disease in SSc is unclear; however, it is 
possible that chronic systemic inﬂ  ammation could pro-
mote accelerated atherosclerosis in patients with SSc.
Endothelial dysfunction
Endothelial dysfunction is a component of the patho-
physiology of both SSc and atherosclerosis (Figure 1). In 
SSc, the initiating injury is unknown, but endothelial cell 
damage leads to enhanced expression of adhesion 
molecules and elevated levels of circulating soluble 
adhesion molecules. Soluble E-selectin, intercellular adhe-
sion molecule-1, and VCAM-1 levels are all signiﬁ  cantly 
increased in SSc, reﬂ  ecting endothelial activation [58]. 
Enhanced endothelial cell expression of adhesion 
molecules results in adhesion of inﬂ  ammatory  cells, 
trans  migration across the vessel wall, and inﬁ  ltration of 
the extracellular matrix. Another important component 
of endothelial dysfunction in SSc is derangement of 
vasoactive mediators, with an increase in vasoconstrictive 
endothelin and a decrease in the vasodilator nitric oxide 
(NO).
In atherosclerosis, endothelial cell dysfunction is the 
common pathway by which factors such as elevated low-
density lipoprotein, elevated plasma homocysteine, 
various infectious agents, and exposure to free radicals 
from smoking, hypertension, and diabetes mellitus are 
proposed to contribute to pathogenesis [55]. Endothelial 
dysfunction leads to upregulation of adhesion molecules 
on the endothelium and increased vessel wall permea-
bility. Lipid-laden monocytes and macrophages known as 
foam cells then accumulate. Migration and proliferation 
of vascular smooth-muscle cells follow, leading to 
remodeling of the vessel wall and atherosclerotic plaque 
formation.
Endothelial progenitor cells
A reduction in the density of blood vessels is one of the 
hallmarks of vascular disease in SSc. Paradoxically, this 
occurs in the setting of increased circulating angiogenic 
factors, such as vascular endothelial growth factor [59]. 
Several theories have been advanced to account for the 
deﬁ   cient angiogenesis in SSc despite the presence of 
permissive vascular growth factors. One explanation is a 
reduction in circulating endothelial progenitor cells 
(EPCs). Asahara and colleagues [60] isolated a population 
of progenitor cells from human peripheral blood which 
were incorporated into sites of new blood vessel forma-
tion when adoptively transferred to an animal model of 
ischemia. Whereas Kuwana and colleagues [61] initially 
showed that EPCs were decreased in SSc, others [62] 
have since demonstrated that these cells are elevated in 
early disease and decrease with increasing disease dura-
tion. EPCs have also been the subject of study in 
cardiovascular disease, in which a decreased number in 
the peripheral circulation has been shown to be predic-
tive of recurrent acute coronary artery events [63].
Nevskaya and colleagues [64] examined the relationship 
between cardiovascular disease and EPCs in 40 patients 
with SSc and found that a decreased EPC count corre-
lated with endothelial dysfunction, as measured by FMD. 
Decreased EPC number did not, however, correlate with 
subclinical atherosclerosis as measured by CIMT [64]. 
Th  ere was also no relationship between EPC count and 
the Framingham risk factor score or the presence of 
traditional cardiovascular risk factors.
Although EPCs are a promising potential biomarker of 
both cardiovascular risk and SSc disease activity, there is 
some debate over their true signiﬁ  cance. Some groups 
have questioned whether the cells isolated by Asahara 
and colleagues [60] and others are true progenitor cells 
that incorporate into new blood vessels or rather are cells 
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blood vessel formation [65]. Th  e development of cell 
lineage markers that are more speciﬁ  c will help elucidate 
the biological properties of these cells.
Microparticles
Microparticles (MPs) are small circulating membrane-
coated vesicles that are important mediators of inter-
cellular signaling. MPs contribute to the immunopatho-
genesis of various thrombotic and rheumatic diseases via 
their role in the regulation of inﬂ  ammation, thrombosis, 
and angiogenesis. MPs arise from a variety of cell types 
and are formed by the process of blebbing during cell 
activation and apoptosis. MP numbers have been shown 
to be elevated in patients with SSc and to correlate with 
the presence of interstitial lung disease [66]. In SSc, MPs 
have been identiﬁ  ed to arise from platelets, endothelial 
cells, monocytes, and T cells, reﬂ   ecting activation of 
these cells. MPs have also been suggested as a biomarker 
of coronary artery disease. High levels of endothelial MPs 
are found in patients with acute MI and result in severe 
endothelial dysfunction by selectively impairing the 
production of NO [67].
Angiotensin-converting enzyme insertion/deletion 
polymorphism
Activation of the renin-angiotensin-aldosterone axis is 
central to the pathogenesis of scleroderma renal crisis, as 
demonstrated by the dramatic improvement in survival 
since ACE inhibitors have been used to treat the condi-
tion. Over a 30-year period that spanned the introduction 
of ACE inhibitors, deaths due to renal crisis decreased 
from 42% to 6% (P <0.005) [12].
An insertion/deletion (I/D) polymorphism of the ACE 
gene has been identiﬁ  ed, and the highest levels of plasma 
ACE are associated with the DD genotype and lowest 
levels are associated with the II genotype [68]. Th  e 
original report of the relationship between this 
polymorphism and acute MI found a risk ratio of 1.34 
(95% conﬁ  dence interval of 1.05 to 1.70) for MI in those 
with the DD genotype compared with those with either 
the II or ID genotype [33]. A later meta-analysis of 
studies concluded that the risk conferred by the DD 
genotype was more modest (risk ratio of 1.0 to 1.1) [69]. 
As described earlier, the ACE gene polymorphism has 
been examined in patients with SSc; in this study, the 
presence of a D allele correlated with increased CIMT 
[32]. Th  ese investigators also reported a correlation 
between the presence of a D allele and an increased risk 
of SSc in the Italian popu  lation [70]; however, this ﬁ  nding 
has not been conﬁ  rmed in other populations [71].
Antiphospholipid antibodies
Th  e presence of anticardiolipin (aCL) or anti-β2-glyco-
protein I (anti-β2GPI) antibodies or both in the absence 
of antiphospholipid syndrome or other autoimmune 
Figure 1. Potential factors contributing to the pathogenesis of cardiovascular disease in systemic sclerosis. EPC, endothelial progenitor cell; 
MP, microparticle; NO, nitric oxide.
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for ischemic heart disease. A study of incident cardio-
vascular events in a population of Hawaiian men of 
Japanese descent found that anti-β2GPI in the presence of 
aCL was independently predictive of incident ischemic 
stroke and MI over 20 years of follow-up [72]. In a study 
of recurrent cardiac events post-infarction, elevated IgG 
aCL and low IgM aCL, but not anti-β2GPI, were indepen-
dent risk factors for recurrent events [73].
An increased prevalence of aCL and anti-β2GPI 
antibodies occurring in the ab    sence of typical clinical 
mani  festations of antiphospholipid syndrome has been 
demonstrated in patients with SSc compared with 
controls [74]. Boin and colleagues [75] showed that anti-
β2GPI is associated with both higher mortality and 
vascular disease, including digital ischemia and PAH, in 
SSc. Th   e authors did not report on the cause of mortality 
or the prevalence of cardiovascular disease in their 
cohort.
Conclusions
Since the introduction of ACE inhibitors for the manage-
ment of scleroderma renal crisis in the 1980s, the overall 
survival of patients with SSc has improved signiﬁ  cantly 
and the relative contribution to mortality of non-SSc 
comorbidities has increased [12]. With better therapies 
for PAH, we are likely to see further improvements in 
survival and non-SSc-related organ dysfunction become 
more apparent. Patients with other chronic inﬂ  ammatory 
diseases such as SLE and RA experience excess cardio-
vascular disease, predominantly due to accelerated 
atherosclerosis, and this may occur in SSc also. Given the 
prominent involvement of the vasculature in SSc and the 
role of inﬂ   ammation in the development of athero-
sclerosis, overlap between these disorders might not be 
that surprising. However, there is a relative paucity of 
data regarding clinical and preclinical cardiovascular 
disease in SSc, whether due to atherosclerosis or micro-
vascular involvement. In particular, adequately sized 
population-based cohort studies of the incidence and 
prevalence of coronary artery disease in SSc relative to 
the general population are lacking. Surrogate markers of 
cardiovascular disease may assist in quantifying the 
burden of subclinical atherosclerosis and may also 
provide insights into the mechanisms underlying the 
development of macrovascular disease in SSc. Recog  ni-
tion of such an association could have important clinical 
ramiﬁ  cations.
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